Table 2. Efficacy of patients with advanced HCC treated with PD-1 inhibitors and regorafenib (n=17).

Outcome	Values
Deaths, n (%)	1 (5.88)
Survivors, n (%)	16 (94.12)
95% CI	10.02, –
OS rate (%)
6 months (95% CI)	100.00% (100.00–100.00%)
9 months (95% CI)	100.00% (100.00–100.00%)
12 months (95% CI)	83.33% (27.31–97.47%)
15 months (95% CI)	83.33% (27.31–97.47%)
Median PFS (months)	5.09 (2.92–12.42)
ORR (%)	41.2
DCR (%)	64.7
Median follow-up time (months) (95% CI)	7.62 (4.76–10.28)

HCC, hepatocellular carcinoma; PD-1, programmed cell death protein 1; CI, confidence interval; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; DCR, disease control rate.